{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:34:18Z","timestamp":1778049258353,"version":"3.51.4"},"reference-count":14,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Biliary tract cancers (BTC) are uncommon malignancies and are underrepresented in the literature. Methods: We performed a retrospective population-based review of adult patients with biopsy-confirmed BTC in Alberta from 2000 to 2015. Demographic data, risk factors, symptoms, treatment, and staging data were collected and analyzed. Survival analyses were completed. Results: A total of 1604 patients were included in our study, of which 766 (47.8%) were male. The median age at diagnosis was 68 (range 19\u201399). There were 374 (23.3%) patients with resectable tumors at diagnosis versus 597 (37.2%) with unresectable tumors. Of the patients, 380 (21.5%) received chemotherapy (CT) and 81 (5.0%) underwent radiation therapy. There was a clear trend with worsening stage and performance status associated with shorter median overall survival (OS). Ampulla of Vater tumors had the best median OS (25.69 months), while intrahepatic bile duct cancers had the worst (5.78 months). First-line palliative CT regimens included gemcitabine+cisplatin (OS 14.98 months (mo), n = 212), single agent gemcitabine (OS 12.42 mo, n = 22), capecitabine (OS 8.12 mo, n = 8), and capecitabine+gemcitabine (OS 6.93 mo, n = 13). Patients with advanced or metastatic disease who received first-line gemcitabine+cisplatin had a median OS of 11.8 months (n = 119). Conclusion: BTCs have poor survival. Worse outcomes occur in higher stage and poorer Eastern Cooperative Oncology Group (ECOG) performance status patients across all tumor subtypes. Tumor resectability at diagnosis was associated with better OS. Our study supports the use of gemcitabine+cisplatin as a combination first-line palliative CT, as patients treated in Alberta have a comparable OS to that reported in the ABC-02 phase III study.<\/jats:p>","DOI":"10.3390\/curroncol28010044","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T04:55:31Z","timestamp":1611032131000},"page":"417-427","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-8348","authenticated-orcid":false,"given":"Carissa","family":"Beaulieu","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, AB T6G 2R3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Lui","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada"},{"name":"Southern Philippines Medical Center, Davao City 8000, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2346-0141","authenticated-orcid":false,"given":"Dimas","family":"Yusuf","sequence":"additional","affiliation":[{"name":"Delta Hospital, Delta, BC V4K 3V6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab","family":"Abdelaziz","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada"},{"name":"Department of Clinical Oncology, Kasr Al-Aini School of Medicine, Cairo 11562, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brock","family":"Randolph","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of Alberta, Edmonton, AB T6G 1K4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Batuyong","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 4N2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver F.","family":"Bathe","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 4N2, Canada"},{"name":"Department of Surgery, University of Calgary, Calgary, AB T2N 2T9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Tam","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 4N2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Spratlin","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada"},{"name":"Department of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.cco.0000129679.49651.50","article-title":"Biliary tract neoplasms: Update 2003","volume":"16","author":"Malka","year":"2004","journal-title":"Curr. Opin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(05)67530-7","article-title":"Cholangiocarcinoma","volume":"366","author":"Khan","year":"2005","journal-title":"Lancet Lond. Engl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cld.2007.11.003","article-title":"Cholangiocarcinoma","volume":"12","author":"Blechacz","year":"2008","journal-title":"Clin. Liver Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MOG.0b013e3282fbf9b3","article-title":"Cholangiocarcinoma: Lessons from Thailand","volume":"24","author":"Sripa","year":"2008","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3322\/canjclin.51.6.349","article-title":"Epidemiology and Molecular Pathology of Gallbladder Cancer","volume":"51","author":"Miquel","year":"2001","journal-title":"CA A Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11605-006-0075-x","article-title":"Diagnosis and Surgical Management of Gallbladder Cancer: A Review","volume":"11","author":"Reid","year":"2007","journal-title":"J. Gastrointest. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/annonc\/mdn533","article-title":"Epidemiology of biliary tract cancers: An update","volume":"20","author":"Randi","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1634\/theoncologist.2007-0252","article-title":"Systemic Therapy for Biliary Tract Cancers","volume":"13","author":"Hezel","year":"2008","journal-title":"Oncologist"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","article-title":"Staging, Resectability, and Outcome in 225 Patients with Hilar Cholangiocarcinoma","volume":"234","author":"Jarnagin","year":"2001","journal-title":"Ann. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.21873\/cgp.20203","article-title":"Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives","volume":"17","author":"Rizzo","year":"2020","journal-title":"Cancer Genom. Proteom."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Rizzo, A., Ricci, A.D., and Brandi, G. (2020). Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: Evidence to date and future perspectives. Expert Opin. Investig. Drugs, 1\u20138.","DOI":"10.1080\/13543784.2021.1837774"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/1\/44\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:10:23Z","timestamp":1760159423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/1\/44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["curroncol28010044"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28010044","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]}}}